MSH Capital Advisors LLC Invests $534,000 in Bristol-Myers Squibb (NYSE:BMY)

MSH Capital Advisors LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,444 shares of the biopharmaceutical company's stock, valued at approximately $534,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $1,989,525,000. Wellington Management Group LLP lifted its position in shares of Bristol-Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after purchasing an additional 5,827,317 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $257,618,000. Schroder Investment Management Group grew its holdings in shares of Bristol-Myers Squibb by 49.7% in the 4th quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock worth $639,837,000 after purchasing an additional 3,787,075 shares during the last quarter. Finally, Independent Franchise Partners LLP boosted its position in Bristol-Myers Squibb by 20.8% in the 4th quarter. Independent Franchise Partners LLP now owns 17,129,229 shares of the biopharmaceutical company's stock valued at $968,829,000 after buying an additional 2,944,879 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BMY. UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Citigroup lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday. They set an "overweight" rating and a $65.00 price target for the company. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $58.13.

Bristol-Myers Squibb Stock Up 2.0 %

Bristol-Myers Squibb stock traded up $0.96 during midday trading on Tuesday, hitting $49.90. 3,311,518 shares of the company were exchanged, compared to its average volume of 12,940,670. The company's fifty day moving average price is $56.83 and its 200-day moving average price is $56.64. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market cap of $101.53 billion, a PE ratio of -11.30, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.97%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.